HPV Type | Bethesda classification | # studies | Reference(s) | # cases | Total sample size | % Prevalence (95% CI) from meta-analysis |
---|---|---|---|---|---|---|
HR‡ | Negative†| 9 | 1451 | 15102 | 40.5% (26.4%-54.6%) | |
 | Benign | 2 | [51] | 42 | 275 | 15.7% (9.3%-22.0%) |
 | ASC-US | 5 | 136 | 350 | 40.5% (26.4%-54.6%) | |
 | LSIL | 10 | 928 | 1563 | 73.6% (55.3%-91.8%) | |
 | HSIL | 8 | 559 | 628 | 89.9% (84.8%-95.1%) | |
 | Cervical Cancer | 2 | 2 | 3 | * | |
16 | Negative | 6 | 473 | 6017 | 7.9% (4.9%-11.0%) | |
 | Benign | 1 | [39] | 2 | 250 | * |
 | ASC-US | 1 | [48] | 0 | 17 | * |
 | LSIL | 7 | 506 | 1925 | 28.3% (15.1%-41.5%) | |
 | HSIL | 7 | 516 | 1068 | 54.0% (45.6%-62.4%) | |
 | Cervical Cancer | 3 | 81 | 172 | 48.8% (34.0%-63.6%) | |
18 | Negative | 5 | 156 | 4891 | 3.6% (1.6%-5.6%) | |
 | Benign | 1 | [39] | 14 | 250 | * |
 | ASC-US | 1 | [48] | 2 | 17 | * |
 | LSIL | 6 | 81 | 1312 | 5.8% (3.6%-7.9%) | |
 | HSIL | 5 | 47 | 662 | 7.9% (3.8%-12.0%) | |
 | Cervical Cancer | 4 | 42 | 219 | 17.1% (6.4%-27.9%) | |
31 | Negative | 4 | 33 | 4849 | 2.1% (0.1%-4.1%) | |
 | Benign | 1 | [39] | 2 | 250 | * |
 | ASC-US | 1 | [48] | 0 | 17 | * |
 | LSIL | 5 | 76 | 1241 | 7.3% (2.7%-11.8%) | |
 | HSIL | 4 | 64 | 432 | 14.2% (4.0%-24.5%) | |
 | Cervical Cancer | 3 | 3 | 172 | 1.2% (0.0%-2.73%) | |
33 | Negative | 4 | 38 | 4849 | 0.6% (0.0%-1.3%) | |
 | Benign | 1 | [39] | 1 | 250 | * |
 | ASC-US | 1 | [48] | 2 | 17 | * |
 | LSIL | 4 | 35 | 884 | 3.6% (1.2%-6.0%) | |
 | HSIL | 4 | 24 | 432 | 5.6% (3.5%-7.8%) | |
 | Cervical Cancer | 3 | 4 | 172 | 2.1% (0.0%-4.2%) | |
35 | Negative | 4 | 28 | 4849 | 0.5% (0.3%-0.8%) | |
 | Benign | 1 | [39] | 1 | 250 | * |
 | ASC-US | 1 | [48] | 0 | 17 | * |
 | LSIL | 4 | 31 | 884 | 3.1% (0.3%-6.0%) | |
 | HSIL | 4 | 8 | 432 | 1.8% (0.5%-3.0%) | |
 | Cervical Cancer | 3 | 0 | 172 | * | |
39 | Negative | 3 | 11 | 4770 | 0.8% (0.0%-2.0%) | |
 | Benign | 1 | [39] | 0 | 250 | * |
 | ASC-US | 1 | [48] | 1 | 17 | * |
 | LSIL | 3 | 6 | 860 | 0.6% (0.0%-1.5%) | |
 | HSIL | 3 | 2 | 374 | * | |
 | Cervical Cancer | 2 | 1 | 96 | * | |
45 | Negative | 3 | 31 | 4770 | 0.6% (0.4%-0.9%) | |
 | Benign | 1 | [39] | 0 | 250 | * |
 | ASC-US | 1 | [48] | 0 | 17 | * |
 | LSIL | 3 | 9 | 860 | 1.1% (0.4%-1.7%) | |
 | HSIL | 3 | 6 | 374 | * | |
 | Cervical Cancer | 2 | 8 | 96 | 7.7% (2.4%-13.0%) | |
51 | Negative | 3 | [39] | 7 | 4470 | * |
 | Benign | 1 | [39] | 0 | 250 | * |
 | ASC-US | 1 | [48] | 1 | 17 | * |
 | LSIL | 3 | 2 | 860 | * | |
 | HSIL | 3 | 3 | 374 | * | |
 | Cervical Cancer | 2 | 0 | 96 | * | |
52 | Negative | 4 | 41 | 5530 | 1.4% (0.1%-2.7%) | |
 | Benign | 1 | [39] | 0 | 250 | * |
 | ASC-US | 1 | [48] | 1 | 17 | * |
 | LSIL | 4 | 50 | 1217 | 2.9% (0.8%-5.1%) | |
 | HSIL | 3 | 9 | 374 | 2.4% (0.9%-4.0%) | |
 | Cervical Cancer | 2 | 3 | 96 | 2.6% (0.0%-7.1%) | |
56 | Negative | 3 | 74 | 4770 | 1.4% (0.8%-2.0%) | |
 | Benign | 1 | [39] | 5 | 250 | * |
 | ASC-US | 1 | [48] | 0 | 17 | * |
 | LSIL | 3 | 52 | 860 | 5.8% (3.2%-8.3%) | |
 | HSIL | 3 | 4 | 374 | * | |
 | Cervical Cancer | 2 | 2 | 96 | 1.6% (0.0%-4.1%) | |
58 | Negative | 4 | 37 | 4849 | 1.0% (0.3%-1.6%) | |
 | Benign | 1 | [39] | 0 | 250 | * |
 | ASC-US | 1 | [48] | 0 | 17 | * |
 | LSIL | 4 | 22 | 884 | 2.3% (1.3%-3.3%) | |
 | HSIL | 4 | 11 | 432 | 2.0% (0.0%-4.3%) | |
 | Cervical Cancer | 2 | 0 | 96 | * | |
59 | Negative | 3 | 25 | 4770 | 0.5% (0.0%-1.1%) | |
 | Benign | 1 | [39] | 2 | 250 | * |
 | ASC-US | 1 | [48] | 1 | 17 | * |
 | LSIL | 3 | 9 | 860 | 0.9% (0.3%-1.6%) | |
 | HSIL | 3 | 9 | 374 | 2.1% (0.7%-3.6%) | |
 | Cervical Cancer | 2 | 0 | 96 | * | |
68 | Negative | 3 | 5 | 4470 | * | |
 | Benign | 1 | [39] | 0 | 250 | * |
 | ASC-US | 1 | [48] | 0 | 17 | * |
 | LSIL | 3 | 1 | 860 | * | |
 | HSIL | 3 | 2 | 374 | * | |
 | Cervical Cancer | 2 | 1 | 96 | * |